

---

## News Release

For Immediate Release

31 October 2013

Contact: **Tricia Thompson**  
Business Development  
+1 (610) 539-3670

### PluroGen Receives Approval to Sell in France

(Norristown, Pennsylvania, USA, 31 October 2013) - PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that it received approval from ANSM, the French Health Authority, to sell its unique and advanced PluroGel® PSSD and PluroGel® Burn and Wound in France.

The Advanced Wound Care Market in France is estimated by the Company to be a \$680 million opportunity for PluroGen. While France is part of the European Union participating in the pan-European CE Mark System of medical device approval, France has its own internal system, managed by its national health authority, ANSM, to allow life science products to be sold. ANSM approval to sell is a big step forward for PluroGen, opening the opportunity to enter the French market.

“PluroGen has achieved another important milestone. Our PluroGel® Products are already achieving superior patient results in the USA and a number of countries in Europe compared to the competition. With ANSM approval, we can now begin our search for corporate partners and distributors in France.” commented Neal Koller, President and CEO of PluroGen. “Having France’s ANSM approval adds another valuable asset to the Company, opens another large market opportunity and enhances shareholder value”.

#### About PluroGen Therapeutics, Inc.

PluroGen Therapeutics, Inc. is a burn, wound, and skin care company providing clinically advanced and superior products from its multiple, patent-protected technology platforms. The Company’s primary platform is its core PluroGel® surfactant technology which provides products with paradigm-shifting, superior and differentiated Core, Bio-Physical, and Performance Functions resulting in unique and advantaged Multi-Function products. Products based on PluroGel® are University developed and are in routine use, having shown superior results on more than 12,000 patients in two different patient populations- severe burns and non-healing wounds. PluroGen’s three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration. PluroGen has a strong new product pipeline and its senior management, operations team, boards and principal investigators are all recognized global, commercial and clinical leaders in PluroGen’s target markets of burn and wound care.

More information can be found on the company web site at [www.plurogen.com](http://www.plurogen.com). For PluroGen Investor Information please call +1 (610) 539-3670.

#### Safe Harbor Statement

The statements in the press release that relate to PluroGen’s (the company) expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company’s actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.